Skip to main navigation Skip to search Skip to main content

Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68

  • Liang Sun
  • , Adam Meijer
  • , Mathy Froeyen
  • , Linlin Zhang
  • , Hendrik Jan Thibaut
  • , Jim Baggen
  • , Shyla George
  • , John Vernachio
  • , Frank J M van Kuppeveld
  • , Pieter Leyssen
  • , Rolf Hilgenfeld
  • , Johan Neyts
  • , Leen Delang

    Research output: Contribution to journalArticleAcademicpeer-review

    Abstract

    The susceptibility of ten EV-68 isolates (belonging to cluster A, B and C) to (entero-)virus inhibitors with different mechanisms of action was investigated. The 3C-protease inhibitors proved to be more efficient than enviroxime and pleconaril, which in turn were more effective than vapendavir and pirodavir. Favipiravir proved a weak inhibitor. Resistance to pleconaril maps to V69A in VP1 and resistance to rupintrivir to V104I in the 3C protease. A structural explanation is provided why both mutations may cause resistance.

    Original languageEnglish
    Pages (from-to)7782-7785
    JournalAntimicrobial Agents and Chemotherapy
    Volume59
    Issue number12
    DOIs
    Publication statusPublished - 14 Sept 2015

    Bibliographical note

    Copyright © 2015, American Society for Microbiology. All Rights Reserved.

    Fingerprint

    Dive into the research topics of 'Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68'. Together they form a unique fingerprint.

    Cite this